Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Bingjie Ding et al, adding:
”TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
This phase 1 trial found oral TQB3473 achieved a 56.8% response rate in relapsed/refractory ITP, with 600 mg daily showing the best efficacy-tolerability balance.”
Title: TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
Authors: Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Anqi Yang, Jiajia Zhu, Yiran Wang, Hu Zhou

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026